证券代码：000078 证券简称：海王生物 公告编号：2025-057 深圳市海王生物工程股份有限公司 第十届董事局第一次会议决议公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、董事局会议召开情况 深圳市海王生物工程股份有限公司（以下简称"公司"）第十届董事局第一 次会议通知于2025年10月17日发出，并于2025年10月24日以现场及视频会议相结 合的形式召开。其中独立董事王焕军先生、张巍松先生、吴野先生，董事张锋先 生、刘德举先生、张翼飞先生、金锐先生、王云雷先生以出席现场会议形式参与 表决；董事车汉澍先生以视频会议形式参与表决。公司第十届董事局高级管理人 员候选人张晓鹏先生、金戈先生、史晓明先生，公司财务总监候选人李爽女士， 审计中心总监候选人吴泽楷先生列席了本次会议。本次会议由半数以上董事推举 董事张锋先生主持召开。会议的召开和表决程序符合《公司法》和《公司章程》 的规定。会议应参与表决董事9人，实际参与表决董事9人。会议的召开和表决程 序符合《公司法》和《公司章程》的规定。 二、董事局会议审议情况 经与会董事审议，会议通过了如下议案： （ ...

证券代码：000078 证券简称：海王生物 公告编号：2025-058 深圳市海王生物工程股份有限公司 第十届董事局第二次会议决议公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、董事局会议召开情况 深圳市海王生物工程股份有限公司（以下简称"公司"）第十届董事局第二 次会议通知于2025年10月17日发出，并于2025年10月24日以现场及视频会议相结 合的形式召开。其中独立董事王焕军先生、张巍松先生、吴野先生，董事张锋先 生、刘德举先生、张翼飞先生、金锐先生、王云雷先生以出席现场会议形式参与 表决；董事车汉澍先生以视频会议形式参与表决。公司第十届董事局高级管理人 员候选人张晓鹏先生、金戈先生、史晓明先生，公司财务总监候选人李爽女士， 审计中心总监候选人吴泽楷先生列席了本次会议。本次会议由董事局主席张锋先 生主持召开。会议的召开和表决程序符合《公司法》和《公司章程》的规定。会 议应参与表决董事9人，实际参与表决董事9人。会议的召开和表决程序符合《公 司法》和《公司章程》的规定。 二、董事局会议审议情况 经与会董事审议，会议通过了如下议案： （一）审议通 ...

Market Overview - The pharmaceutical commercial sector increased by 0.44% on October 23, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Jianfa Zhixin (301584) saw a significant rise of 20.00%, closing at 37.20 with a trading volume of 301,100 shares and a transaction value of 1.046 billion [1] - Other notable performers included: - Kaikai Industrial (600272) up 2.20% to 13.49 [1] - First Pharmaceutical (600833) up 1.97% to 14.01 [1] - Dazhenlin (603233) up 1.48% to 19.20 [1] - Yifeng Pharmacy (603939) up 1.31% to 25.44 [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 97.0483 million from institutional investors and 117 million from speculative funds, while retail investors saw a net inflow of 214 million [2] - The capital flow for key stocks showed: - Jianfa Zhixin had a net inflow of 1.22 billion from institutional investors, but a net outflow of 58.2871 million from speculative funds [3] - Kaikai Industrial had a net inflow of 15.4487 million from institutional investors, with a net outflow of 3.9622 million from speculative funds [3]

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

Group 1 - The company, Shenzhen Sea King Biological Engineering Co., Ltd., is convening its second extraordinary general meeting of shareholders in 2025 on October 24, 2025 [3][4] - The meeting will be conducted through a combination of on-site voting and online voting [5][6] - The meeting's legal compliance has been confirmed according to relevant laws and regulations [4][6] Group 2 - The meeting will take place at 14:50 on October 24, 2025, with online voting available from 9:15 to 15:00 on the same day [5][9] - Shareholders must register to attend the meeting, with specific registration methods outlined for individual and institutional shareholders [9][12] - The agenda includes multiple proposals, with some requiring cumulative voting and special resolutions needing a two-thirds majority to pass [7][8] Group 3 - The company has ensured that all disclosures regarding the meeting are accurate and complete [3] - The meeting will allow shareholders to appoint proxies for voting, and detailed procedures for online voting are provided [10][21] - Contact information for the company is available for any inquiries related to the meeting [12]

Core Viewpoint - Haiwang Bio (000078) announced revisions to its Articles of Association and multiple company systems to enhance corporate governance and operational standards [1][5]. Group 1: Background and Reasons for Revisions - The revisions are based on legal requirements from the Company Law and related regulatory documents, tailored to the company's actual situation [2]. - The supervisory board's powers will be transferred to the board's audit committee, leading to the abolition of the supervisory board's meeting rules [2]. Group 2: Key Points of the Articles of Association Revisions - Legal representative provisions clarify that if a director or president resigns, they are deemed to have also resigned as the legal representative, with a new representative to be appointed within 30 days [3]. - Shareholder rights and obligations have been detailed, including the right to request the company to buy back shares in case of dissent regarding merger or division resolutions [3]. - Directors' duties have been reinforced, emphasizing loyalty and diligence, with provisions for income from violations to be returned to the company and liability for losses incurred [3]. - The governance structure will see the audit committee assume the supervisory board's functions, with defined roles and procedures for the nomination and remuneration committees [3]. Group 3: Revisions to Meeting Rules - The "Shareholders' Meeting Rules" have been updated to replace "Shareholders' General Meeting" with "Shareholders' Meeting" and adjust procedures for convening temporary meetings and voting rules [4]. - The "Board Meeting Rules" have been refined to enhance the election, replacement, and resignation processes of directors, emphasizing the independence and responsibilities of independent directors [4]. Group 4: Implementation of Revised Systems - A total of 26 company systems have been established or revised, covering areas such as shareholder meetings, board meetings, auditing, and fundraising management [5]. - Six of these systems, including the "Shareholders' Meeting Rules" and "Board Meeting Rules," require approval from the shareholders' meeting to take effect, while others will be effective upon board approval [5]. - The merger of the "Independent Director Special Meeting System" into the "Independent Director Work System" has been executed, with the former being abolished [5].

Core Viewpoint - Shenzhen Haiwang Bioengineering Co., Ltd. has released a draft of its revised company articles aimed at improving corporate governance, operational efficiency, and protecting the rights of shareholders and the company [1][2]. Group 1: Company Structure and Governance - The company was established in 1998 with a registered capital of RMB 2,631,123,257.00, and it operates in various fields including biochemical raw materials, pharmaceuticals, and investment [1][2]. - The total number of shares is 2,631,123,257, all of which are ordinary shares, with initial issuance of 57,300,000 shares by five founding shareholders [2]. - The governance structure includes a board of directors consisting of 7 to 9 members, with independent directors making up at least one-third of the board [2]. Group 2: Shareholder Rights and Responsibilities - Shareholders have rights to dividends and participation in shareholder meetings, while also being required to comply with legal obligations and company regulations [2]. - The shareholder meeting is responsible for major decisions such as director elections and profit distribution, with specific procedures for convening and voting [2]. Group 3: Financial and Audit Regulations - The company is required to establish financial accounting systems and disclose annual and interim reports in a timely manner [2]. - Profit distribution policies will focus on investor returns and may include cash or stock options, depending on the company's development stage [2]. - An internal audit system is in place to oversee financial practices and the appointment of external auditors [2].

深圳市海王生物工程股份有限公司 董事局秘书工作制度 （2025年9月修订) 第一章 总则 第一条 为了促进深圳市海王生物工程股份有限公司(以下简称"公司")的规 范运作，充分发挥董事局秘书的作用，加强对董事局秘书工作的管理与监督， 根据《中华人民共和国公司法》（以下简称《公司法》）《中华人民共和国证券 法》《深圳证券交易所股票上市规则》（以下简称"上市规则"）《深圳证券交易 所上市公司自律监管指引第1号——主板上市公司规范运作》等有关法律、行政法 规、部门规章、规范性文件及《深圳市海王生物工程股份有限公司章程》（以下简 称"《公司章程》"）的规定，制定本工作制度。 第二条 董事局秘书是公司与深圳证券交易所之间的指定联络人。公司应当 为董事局秘书履行职责提供便利条件，董事、财务负责人及其他高级管理人员 和相关工作人员需支持、配合董事局秘书的工作。董事局秘书为履行职责有权 了解公司的财务和经营情况，参加涉及信息披露的有关会议，查阅涉及信息披 露的所有文件，并要求公司有关部门和人员及时提供相关资料和信息。公司做 出重大决定之前，应当从信息披露角度征询董事局秘书的意见。 第二章 董事局秘书职责 第三条 公司设董事局秘 ...

第四条 公司的董事和高级管理人员应当遵守信息披露工作内控制度的要求， 对公司定期报告、临时公告及重大事项履行必要的传递、审核和披露流程。 第五条 公司的董事和高级管理人员及其他相关涉密人员在定期报告编制、 公司重大事项筹划期间，负有保密义务。定期报告、临时报告公布前，不得以任何 形式、任何途径向外界或特定人员泄漏定期报告、临时报告的内容，包括但不限于 业绩座谈会、分析师会议、接受投资者调研座谈等方式。 深圳市海王生物工程股份有限公司 外部信息报送和使用管理制度 （2025 年 9 月修订) 第一条 为加强公司对外部信息报送和使用的管理，规范公司在定期报告及 重大事项编制、审议和披露期间向外单位报送和使用信息的行为，依据《中华人 民共和国公司法》《中华人民共和国证券法》《深圳证券交易所股票上市规则》 《深圳市海王生物工程股份有限公司章程》（以下简称"《公司章程》"）《深圳 市海王生物工程股份有限公司信息披露管理制度》等有关规定，制定本制度。 第二条 本制度适用于公司及子公司、公司董事、高级管理人员及其他有关 人员。 第三条 本制度所指信息指所有对公司股票交易价格可能产生影响的信息， 包括但不限于定期报告、临时公 ...

深圳市海王生物工程股份有限公司 年报信息披露重大差错责任追究制度 （2025 年 9 月修订） 第一章 总则 第一条 为了提高公司的规范运作水平，加大对年报信息披露责任人的问责 力度,提高年报信息披露的质量和透明度,增强年报信息披露的真实性、准确性、 完整性和及时性,根据有关法律、法规规定，结合公司实际情况，制定本制度。 第二条 本制度所指责任追究制度是指年报信息披露工作中有关人员不履行 或者不正确履行职责、义务或其他个人原因，对公司造成重大经济损失或造成不 良社会影响时的追究与处理制度。 第三条 本制度适用于公司董事、高级管理人员、子公司负责人、控股股东 及实际控制人以及与年报信息披露工作有关的其他人员。 第四条 实行责任追究制度，应遵循以下原则：实事求是、客观公正、有错 必究；过错与责任相适应；责任与权利对等原则。 第五条 公司董事局办公室在董事局秘书领导下负责收集、汇总与追究责任 有关的资料，按制度规定提出相关处理方案，逐级上报公司董事局批准。 第二章 年报信息披露重大差错的责任追究 （一）违反《中华人民共和国公司法》《中华人民共和国证券法》《企业会 计准则》和《企业会计制度》等国家法律法规的规定，使年 ...